University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Biostatistics and Epidemiology Faculty
Publications Series

Biostatistics and Epidemiology

2021

Per- and polyfluoroalkyl substances and kidney function: Followup results from the Diabetes Prevention Program trial
Pi-I D. Lin
Andres Cardenas
Russ Hauser
Diane R. Gold
Ken P. Kleinman

See next page for additional authors

Follow this and additional works at: https://scholarworks.umass.edu/bioepi_faculty_pubs
Part of the Biostatistics Commons, and the Health Policy Commons

Authors
Pi-I D. Lin, Andres Cardenas, Russ Hauser, Diane R. Gold, Ken P. Kleinman, Marie-France Hivert, Antonia M.
Calafat, Thomas F. Webster, Edward S. Horton, and Emily Oken

Environment International 148 (2021) 106375

Contents lists available at ScienceDirect

Environment International
journal homepage: www.elsevier.com/locate/envint

Per- and polyfluoroalkyl substances and kidney function: Follow-up results
from the Diabetes Prevention Program trial
Pi-I D. Lin a, Andres Cardenas b, Russ Hauser c, Diane R. Gold c, d, Ken P. Kleinman e,
Marie-France Hivert a, f, Antonia M. Calafat g, Thomas F. Webster h, Edward S. Horton i,
Emily Oken a, *
a

Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA, USA
Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, CA, USA
c
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA
d
Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, MA, USA
e
Department of Biostatistics, School of Public Health and Human Sciences, University of Massachusetts Amherst, Amherst, MA, USA
f
Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
g
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
h
Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA
i
Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
b

A R T I C L E I N F O

A B S T R A C T

Handling Editor: Martí Nadal

Per- and polyfluoroalkyl substances (PFAS) are ubiquitously detected in populations worldwide and may hinder
kidney function. The objective of the study was to determine longitudinal associations of plasma PFAS con
centrations with estimated glomerular filtration rate (eGFR) and evaluate whether a lifestyle intervention modify
the associations. We studied 875 participants initially randomized to the lifestyle or placebo arms in the Diabetes
Prevention Program (DPP, 1996–2002) trial and Outcomes Study (DPPOS, 2002–2014). We ran generalized
linear mixed models accounting a priori covariates to evaluate the associations between baseline PFAS concen
trations and repeated measures of eGFR, separately, for six PFAS (PFOS, PFOA, PFHxS, EtFOSAA, MeFOSAA,
PFNA); then used quantile-based g-computation to evaluate the effects of the six PFAS chemicals as a mixture.
The cohort was 64.9% female; 73.4% 40–64 years-old; 29.4% with hypertension; 50.5% randomized to lifestyle
intervention and 49.5% to placebo and had similar plasma PFAS concentrations as the general U.S. population in
1999–2000. Most participants had normal kidney function (eGFR > 90 mL/min/1.73 m2) over the approximately
14 years of follow-up. We found that plasma PFAS concentrations during DPP were inversely associated with
eGFR during DPPOS follow-up. Each quartile increase in baseline plasma concentration of the 6 PFAS as a
mixture was associated with 2.26 mL/min/1.73 m2 lower eGFR (95% CI: − 4.12, − 0.39) at DPPOS Year 5,
approximately 9 years since DPP randomization and PFAS measurements. The lifestyle intervention did not
modify associations, but inverse associations were stronger among participants with hypertension at baseline.
Among prediabetic adults, we found inverse associations between baseline plasma PFAS concentrations and
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measures of eGFR throughout 14 years of follow-up. The lifestyle intervention of diet, exercise and behavioral
changes did not modify the associations, but persons with hypertension may have heightened susceptibility.

1. Introduction

2. Methods

Per- and polyfluoroalkyl substances (PFAS) are a large group of
nonbiodegradable synthetic chemicals ubiquitously detected in the
environment worldwide. First manufactured in 1950s, PFAS are widely
used in industrial and consumer products, including firefighting foams,
non-stick cookware, food packaging, stain-, grease- and water-resistant
products (ATSDR, 2018). PFAS are ubiquitously detected in human
populations and many also have long elimination half-lives in humans,
e.g., 5.3 years for perfluorohexanesulfonic acid (PFHxS), 3.4 years for
perfluorooctanesulfonic acid (PFOS), 2.7 years for perfluorooctanoic
acid (PFOA) (Li et al., 2018). More than 98% of blood samples collected
from participants in the U.S. National Health and Nutrition Survey
(NHANES) contained detectable concentrations of select PFAS (Calafat
et al., 2007; Kato et al., 2011a, 2011b). Exposure to PFAS has been
linked with obesity, diabetes, hyperlipidemia and microvascular dis
ease, conditions that are themselves associated with poorer kidney
function (Cardenas et al., 2017a, 2019; Lin et al., 2019; Smurthwaite
et al., 2018). Furthermore, the kidney is a primary route for PFAS
elimination (Kjølholt and Warming, 2015). Once certain PFAS enter the
human body, it may take up to several years to eliminate them (Olsen
et al., 2007) and continued exposure leads to bioaccumulation. PFAS
have been shown to cause renal hypertrophy and histopathologic
changes (Cui et al., 2009) and alter renal microvascular endothelial-cell
permeability through increased production of reactive oxidative species.
The proximal tubules have been shown to actively secrete and reabsorb
PFAS (Stanifer et al., 2018).
Systematic reviews of the PFAS literature found evidence that PFAS
is an emerging environmental threat to kidney health (Ferrari et al.,
2019; Stanifer et al., 2018). Currently, most epidemiological evidence
from population-based studies on PFAS biomarkers and kidney diseases
is cross-sectional (Dhingra et al., 2017; Kataria et al., 2015; Shankar
et al., 2011; Watkins et al., 2013), and reverse causation has been a main
concern, i.e. that PFAS concentration in blood increases as kidney
function declines. More findings from longitudinal data are needed to
address the potential gap causal link between PFAS and kidney health
(Ferrari et al., 2019; Stanifer et al., 2018; Wang et al., 2019). The two
available studies that used longitudinal data showed contradictory
findings. Blake et al. found that higher serum PFHxS, perfluorononanoic
acid (PFNA), and perfluorodecanoic acid (PFDA) were associated with
lower prospective measures of eGFR but N-methyl-perfluorooctane
sulfonamido acetic acid (MeFOSAA) was associated with higher eGFR.
However, Dhingra et al. concluded reduced eGFR was the cause rather
than the result of elevated serum PFOA level (Blake et al., 2018; Dhingra
et al., 2017). Both studies used community-exposed cohorts which had
higher PFAS exposure than the U.S. general population.
In this study, we used a longitudinal cohort of prediabetic adults to
test the relationship between commonly detected PFAS and kidney
function over 14 years of follow-up. We implemented directed acyclic
graphs (DAGs) to assess variables that may confound the relationship
and used multiple approaches to address the issue of reverse causation in
this association. Our study question was whether baseline PFAS con
centrations, as individual exposure and as a mixture, were associated
with repeated measures of estimated glomerular filtration rate (eGFR)
over time, and whether lifestyle intervention could modify this associ
ation. We hypothesized higher baseline PFAS concentrations would be
associated with lower eGFR over time. We also hypothesized that an
initial lifestyle intervention of diet, exercise and behavioral changes
could reduce this detrimental effect.

2.1. Study population
The Diabetes Prevention Program (DPP) was a randomized
controlled trial to prevent or delay the onset of type 2 diabetes using
lifestyle or pharmacological intervention, relative to medication placebo
(Diabetes Prevention Program Research Group, 1999, 2000). The trial
recruited obese and overweight adults ≥ 25 years with elevated fasting
glucose from 27 clinical centers across the United States between 1996
and 1999, and randomized participants into three arms: a pharmaco
logical intervention (metformin), a medication-placebo control, or a
lifestyle intervention (Knowler et al., 2002). The lifestyle intervention
arm contained a goal-based behavioral intervention to achieve 7%
weight loss and maintenance of weight loss; each participant had a
personal lifestyle coach or case manager who delivered the intervention
and provided frequent follow-up and contacts to ensure achievement
and maintenance of weight and physical activity goals (Diabetes Pre
vention Program Research Group, 2002a,b). Both the lifestyle and
metformin interventions demonstrated effectiveness in preventing type
2 diabetes (Knowler et al., 2002). All participants were offered a
modified version of the lifestyle intervention after DPP ended (Diabetes
Prevention Program Research Group, 2009, 2012) and were offered
follow up in Diabetes Prevention Program Outcome Study (DPPOS)
which started in 2002 (Diabetes Prevention Program Research Group,
2015). For this analysis, we captured the exposure (plasma PFAS) during
the DPP phase (from baseline recruitment to DPP intervention) and the
outcome (eGFR) from DPPOS follow-up (after the DPP intervention
phase ended) to allow for the prospective temporal order between
exposure and outcome (eFigure 1). Participants enrolled in the DPP
intervention phase for an average (standard deviation, SD) of 3.1 (0.7)
years (for this sub-cohort), and had up to 11 annual visits during DPPOS;
the total follow-up time since DPP baseline randomization was 13.9
(2.6) years (eTable 1).
This prospective analysis was restricted to participants initially
randomized to the lifestyle and placebo arms; 957 (46.6%) had enough
blood volume remaining in the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) Repository for plasma PFAS
measurements. We did not measure PFAS among participants in the
metformin arm given the unknown interaction between metformin and
PFAS and the protective effect of metformin on diabetic kidney disease.
Both DPP and DPPOS study phases have little missing data (only N = 1
missing all eGFR measures among those with PFAS measurements) so
we used complete case analysis in this study (Diabetes Prevention Pro
gram Research Group, 2015). After excluding participants with missing
covariates and removing extreme values for eGFR, the final longitudinal
analysis included 875 participants (see study flow chart in eFigure 1).
All DPP/DPPOS protocols were approved by the institutional review
board (IRB) at each clinical center and Harvard Pilgrim Health Care IRB
reviewed and approved the protocol for this current analysis. The
involvement of the Centers for Disease Control and Prevention (CDC)
laboratory did not constitute engagement in human subjects research.
2.2. Plasma PFAS concentrations
We retrieved plasma samples stored at the NIDDK repository (https
://repository.niddk.nih.gov) for analyses at the CDC laboratory. The
modified on-line solid-phase extraction-high performance liquid
chromatography-isotope dilution-tandem mass spectrometry method
(Cardenas et al., 2017a, Kato et al., 2011a, 2011b), also used to analyze
NHANES PFAS samples, yielded limit of detections (LOD) of 0.1 ng/mL
2
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for all PFAS. Measurements < LOD were imputed as LOD/√2 (Hornung
and Reed, 1990). This analysis included 6 PFAS with detection fre
quency > 80% [PFOS, PFOA, PFHxS, N-ethyl-perfluorooctane sulfona
mido acetic acid (EtFOSAA), MeFOSAA, and PFNA]. Concentrations of
PFOS and PFOA were calculated as the sum of their respective isomers:
linear perfluorooctanesulfonic acid PFOS (n-PFOS), sum of per
fluoromethylheptane sulfonic acid isomers (Sm-PFOS), and sum of
perfluorodimethylhexane sulfonic acid isomers (Sm2-PFOS) for PFOS;
and linear perfluorooctanoic acid (n-PFOA) and sum of per
fluoromethylheptanoic and perfluorodimethylhexanoic acids (Sb-PFOA)
for PFOA; we performed imputation for concentrations < LOD before
summing which was consistent with the method used in the Fourth
National Report on Human Exposure to Environmental Chemicals
(Centers for Disease Control and Prevention, 2019). We calculated the
average concentrations of baseline and the DPP Year 2 measures
(referred to as baseline PFAS from now on), which had been shown to
adequately reflect the relative PFAS body burden considering the rela
tively long half-lives of many PFAS (Cardenas et al., 2017a; Cardenas
et al., 2019; Lin et al., 2020a). The year of blood collection ranged be
tween 1996 and 1999 for baseline and 1998 to 2001 for DPP Year 2. The
concentrations between the two measurements did not change signifi
cantly for all participants, which was expected considering the relatively
long biological half-lives of most PFAS. The temporal pattern and geo
metric means of all 6 PFAS were comparable to those observed in US
NHANES adults (Cardenas et al., 2017a).

outcome assessment. Hypertension status was defined as self-reported
hypertension diagnosis, use of anti-hypertensive medications or sys
tolic/diastolic BP ≥ 140/90 mmHg. We modeled time and age (using the
“mid-point” age described in the previous section) as continuous vari
ables and the rest as categorical variables (see categorization in Table 1).
We evaluated dietary habits using the Dietary Approaches to Stop Hy
pertension (DASH) score, which we previously found to be associated
with plasma PFAS concentrations (Lin et al., 2020b). We evaluated uses
of kidney medications [angiotensin-converting enzyme (ACE) in
hibitors, angiotensin-receptor blockers (ARBs), beta-blockers] based on
self-reported prescriptions.
2.5. Statistical analyses
We used descriptive analysis to report participants’ characteristics,
applied visual inspection to detect outliers, and used normality tests to
assess the distributions of each variable. Plasma PFAS concentrations
were right-skewed, thus we log-2 transformed them. In the main analysis
we examined differences in the eGFR during DPPOS by baseline PFAS
plasma concentrations. Because Sm2-PFOS concentrations were <LOD
in more than 50% of the samples and the median concentration was
close to the LOD (0.1 ng/mL), we also treated Sm2-PFOS as a binary
variable (detected vs non-detected) in the analysis. We applied
Table 1
Baseline characteristics of study participants.

2.3. Kidney function
As previously reported, DPP/DPPOS used Roche reagents on the
Hitachi 917 autoanalyzer (Boehringer Mannheim, Mannheim, Ger
many) to measure serum creatinine (Kim et al., 2019). We extracted
annual laboratory results of serum creatinine for DPPOS years 1 to 11
annual visits for our analysis; 62% of the 875 participants had all 11
annual measures and more than 90% had more than 5 measures (eTa
ble 2). We used the 2009 Chronic Kidney Disease Epidemiology
collaboration (CKD-EPI) serum creatinine equation (Levey et al., 2006)
to calculate eGFR. Due to privacy protection, we did not have partici
pants’ actual age, so we used the following “mid-point” for each age
category: 38 for <40 years; 42 for 40–44 years; 47 for 45–49 years; 52
for 50–54 years; 57 for 55–59 years; and 62 for 60–64 years; 67 for 65+
years). We recognize the use of 67 for the 65+ age group may introduce
bias considering accelerating declines in eGFR with age, so we also
performed sensitivity analyses using 70 and 75 as the imputed age for
this oldest group. To avoid healthy participant bias, we included eGFR
data only for DPPOS Years 1 to 8 annual visits for the final longitudinal
analysis so more than 90% of the participants had eGFR measures at all
annual follow-up visits; this covered approximately 4.5 to 11.4 years
since baseline (time point of PFAS measurements). We also included all
available DPPOS follow-up data (up to 11th annual visits) in the sensi
tivity analysis (eTable 1). Although eGFR is not a perfect measure of
kidney function, due to data availability, we decided to use eGFR which
can also produce comparable results with previous studies. We also had
measures urine albumin-to-creatinine ratios (ACRs), but only at DPP
baseline. We defined elevated ACR, or microalbuminuria, as ACR ≥ 30
mg/g.
2.4. Covariates
We selected covariates a priori based on study questions and used
DAGs to identify potential confounders as well as mediators that could
be in the causal pathway between plasma PFAS concentration and eGFR
(eFigure 2). The following information was extracted directly from the
NIDDK data repository: age category, sex, race/ethnicity, education,
marital status, income, smoking status, treatment arm, baseline micro
albuminuria, hypertension status, menopause status, diabetes status at
the end of DPP phase, and time (years since randomization) of each

Characteristics

N(%), or mean ± SD

Sample size, N
Group assignment
Lifestyle
Placebo
Sex
Male
Female
Race/ethnicity
Non-Hispanic White
African American
Hispanic of any race
All others
Age at DPP enrollment (years)
<40
40–44
45–49
50–54
55–59
60–64
>65
Educational attainment
<High school
High school/GED
College
Graduate school
Marital Status
Married/Cohabitating
Single
Divorced
Widowed
Income
<$20,000
$20,000 - <$35,000
$35,000 - <$50,000
$50,000 - <$75,000
≥75,000
Refused to answer
Current smoker
Menopausal, % among female participants
Hypertension diagnosis
Use of kidney medicationa
DASH Diet Score (0–9 range)
Microalbuminuria at baseline (ACR ≥ 30 mg/g)
Developed diabetes during DPP

875

a

3

442 (50.5)
433 (49.5)
307 (35.1)
568 (64.9)
502 (57.4)
171 (19.5)
163 (18.6)
37 (4.5)
95 (10.9)
100 (11.4)
196 (22.4)
155 (17.7)
130 (14.9)
97 (11.1)
102 (11.7)
41 (4.7)
183 (20.9)
427 (48.8)
224 (25.6)
590 (67.4)
107 (12.2)
138 (15.8)
40 (4.6)
107 (12.2)
159 (18.2)
173 (19.8)
166 (19.0)
196 (22.4)
74 (8.5)
52 (5.9)
307 (54.0)
262 (29.4)
72 (8.2)
2.5 ± 1.6
41 (4.7)
483 (55.2)

Kidney medication: ACE-inhibitor, ARBs, beta-blockers.
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generalized linear mixed models with random intercepts and slopes and
used restricted maximum likelihood for estimation to estimate the lon
gitudinal association between baseline PFAS and annual measures of
eGFR during DPPOS (approximately 3–16 years after the baseline PFAS
measurement, see eFigure 1 and eTable 1 for DPP/DPPOS timeline).
We tested models with different correlation structures, added quadratic
and cubic terms for the follow-up time based on visual inspection of
scatter plot and eGFR trajectories, and evaluated interactions between
parameters. We selected the final model based on study questions and
model fit using the likelihood ratio test for nested models (see detailed
information in Appendix A). We reported parameter estimates of the
fixed effect that estimated the differences in mean eGFR per doubling of
plasma PFAS concentrations across the study period adjusted for cova
riates; evaluated potential effect modification of the longitudinal asso
ciations by sex, treatment arm, and baseline hypertension status, by
adding a multiplicative term between plasma PFAS concentrations and
each effect modifier in the model; and conducted additional stratified
analyses if the multiplicative term had p < 0.10. We tested reverse
causation of effect by using baseline eGFR at DPP as the exposure and
repeated measures of plasma PFAS concentrations (measured at base
line, DPP Year 2 annual visit and DPPOS Year 10 annual visits) as out
comes in the longitudinal models (see detailed equation of the model in
Appendix A).
We performed mixture analysis using quantile-based g-computation
(Keil et al., 2020) to estimate the effect of the 6 PFAS as a mixture with
eGFR measured at the DPPOS Year 5 (mean 8.4 years since randomi
zation) as the outcome, a timepoint when outcome measures were
available for more than 90% of the study participants (eTable 1).
Quantile g-computation (Keil et al., 2020) estimates the effect of an
exposure mixture index that is a weighted average of all exposure after
transforming PFAS concentrations into quartiles, and produces effect
estimates that can be interpreted as mean difference in eGFR across
quantile range of the plasma PFAS concentrations as a mixture. We
evaluated both linear and nonlinear effects and present the mixture
slope with overall model confidence bounds (estimated by 1000 boot
straps) as well as pointwise comparison of the expected difference in
eGFR at each quartile of PFAS concentration with respect to the 2nd
quartile using the gqcomp R package (https://cran.r-project.org/web/
packages/qgcomp/vignettes/qgcomp-vignette.html
version
1.3
defaults).
As a sub-analysis, we performed cross-sectional analyses of plasma
PFAS concentrations with eGFR and ACR at DPP baseline using linear
regression to compare with most previous literature. We assessed the
linearity using generalized additive models. For sensitivity analyses, we
accounted for additional variables in the longitudinal models and mix
tures analysis, including baseline eGFR level, diabetic status at the
beginning of DPPOS, and elevated ACR at baseline. However, since these
variables were likely mediators between the associations of plasma PFAS
concentrations and kidney function (eFigure 2), we did not include
them in the main analysis. We also ran sensitivity analyses using 70 and
75 as the imputed age for estimating the eGFR for the 65 + age group.
We performed the statistical modeling using SAS Studio and R version
3.6.0. Reporting of the manuscript follows the guidelines and checklist
for Strengthening the Reporting of Observational Studies in Epidemi
ology (STROBE) (Von Elm et al., 2007).

microalbuminuria at baseline, and 55.2% developed diabetes at the start
of DPPOS follow-up (Table 1). Average plasma PFAS concentrations
were comparable to the general U.S. population concentrations during
1999–2000 (Centers for Disease Control and Prevention, 2019) and did
not differ across the two treatment arms. Concentrations of all PFAS
were positively correlated (eFigure 3). PFOS [median (interquartile
range, IQR): 27.6 ng/mL (19.2, 38.9)] and PFOA [5.5 ng/mL (3.8, 7.4)]
were the two PFAS detected at the highest concentrations (Table 2).
Most participants had normal eGFR (>90 mL/min/1.73 m2)
throughout DPP/DPPOS (Table 2). At baseline, the mean (STD) eGFR
was 111.05 (38.0) mL/min/1.73 m2 and 87.2% had normal eGFR
(Table 2).
3.2. Longitudinal associations of PFAS with eGFR
We used DAGs to evaluate the appreciate covariates to adjust for in
assessing the longitudinal relationship between baseline PFAS and
repeated measures of eGFR (eFigure 2A) and described the model
evaluation and selection process in detail in Appendix A. After con
trolling for baseline covariates including age, sex, race/ethnicity, edu
cation, marital status, income, smoking status, menopause status, DASH
diet score, hypertension status, and use of kidney medication, we
observed inverse associations of PFOS and PFOA isomers with eGFR;
each doubling of plasma total PFOS concentrations were associated with
1.50 mL/min/1.73 m2 lower eGFR (95% CI: − 2.81, − 0.19) ; and each
doubling of n-PFOA and Sb-PFOA were associated with 1.49 (95% CI:
− 2.97, 0.00) and 0.85 (95% CI: − 1.58, − 0.12) mL/min/1.73 m2 lower
eGFR, respectively (Table 3). The effect estimates were robust with
additional adjustment for diabetic status (eTable 3). When adjusting for
baseline eGFR, which was a potential mediator between plasma PFAS
Table 2
Plasma concentrations of PFAS and kidney function during study follow-up.

3. Results
3.1. Participant characteristics and plasma PFAS concentrations
We included 875 DPP/DPPOS participants in this analysis: 442
(50.5%) from the lifestyle arm and 433 (49.5%) from the placebo arm.
At baseline, participants were 64.9% female; 57.4% non-Hispanic
White, 66.4% 40–59 years old; 74.4% college graduates; 67.4% mar
ried/cohabitating; 41.4% with annual income >$50,000; 5.9% smokers;
29.4% with hypertension.; 8.2% used kidney medication, 4.7% had

Exposure
(PFAS)a

N

Median (IQR) (ng/mL)

Total PFOS
n-PFOS
Sm-PFOS
Sm2-PFOS
Total PFOA
n-PFOA
Sb-PFOA
PFHxS
EtFOSAA
MeFOSAA
PFNA
Outcome
eGFR

875
875
875
875
875
875
875
875
875
875
875
N

27.6 (19.2, 38.9)
19.9 (13.6, 28.2)
7.5 (5.2, 10.9)
0.1 (0.1, 0.3)
5.5 (3.8, 7.4)
4.7 (3.4, 6.2)
0.6 (0.4, 1.0)
2.4 (1.6, 3.8)
1.2 (0.7, 2.0)
1.1 (0.7, 1.7)
0.6 (0.4, 0.9)
Mean (STD) (mL/
min/1.73 m2)

Percent of participants with normal
eGFR (>90 mL/min/1.73 m2)

DPPOS Year
1
DPPOS Year
2
DPPOS Year
3
DPPOS Year
4
DPPOS Year
5
DPPOS Year
6
DPPOS Year
7
DPPOS Year
8
DPPOS Year
9
DPPOS Year
10
DPPOS Year
11

811

111.0 (40.2)

79.4

868

106.7 (24.4)

79.2

845

105.3 (22.7)

77.6

826

100.9 (18.6)

71.2

843

101.2 (19.1)

71.4

814

102.1 (22.0)

70.4

780

99.4 (19.4)

67.4

788

98.0 (19.2)

63.3

773

96.9 (18.9)

61.7

771

96.7 (19.6)

58.8

748

96.8 (19.7)

56.0

a

4

Average of baseline and DPP Year 2.
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Table 3
Associations between PFAS plasma concentration and mean change in eGFR during DPPOS follow-up estimated using generalized mixed modelsa, overall and stratified
according to baseline hypertension status.
Log-2 PFAS analyte

Total PFOS
n-PFOS
Sm-PFOS
Sm2-PFOSd
Total PFOA
n-PFOA
Sb-PFOA
PFHxS
EtFOSAA
MeFOSAA
PFNA

Full

Stratified

(N = 875)
β (95% CI)

Hypertensionb (N = 262)
β (95% CI)

No hypertension (N = 613)
β (95% CI)

pintc

¡1.50 (− 2.81, ¡0.19)
¡1.34 (− 2.62, ¡0.06)
¡1.56 (− 2.85, ¡0.28)
¡1.87 (− 2.88, ¡0.86)
− 1.35 (− 2.73, 0.02)
¡1.49 (− 2.97, ¡0.01)
¡0.85 (− 1.58, ¡0.12)
0.21 (− 0.79, 1.21)
− 0.15 (− 0.97, 0.65)
− 0.62 (− 1.71, 0.45)
0.18 (− 0.90, 1.27)

− 2.19 (− 4.92, 0.53)
− 1.98 (− 4.62, 0.66)
− 2.15 (− 4.89, 0.57)
− 2.66 (− 4.73, − 0.60)
− 3.18 (− 5.85, − 0.51)
− 3.16 (− 5.98, − 0.35)
− 1.66 (− 3.11, − 0.21)
¡2.35 (− 4.46, ¡0.25)
0.02 (− 1.63, 1.68)
− 1.56 (− 3.82, 0.69)
¡1.85 (− 4.20, 0.49)

− 1.44 (− 2.96, 0.06)
− 1.30 (− 2.79, 0.17)
− 1.49 (− 2.96, − 0.02)
− 1.58 (− 2.75, − 0.41)
− 0.65 (− 2.30, 0.99)
− 0.83 (− 2.63, 0.96)
− 0.55 (− 1.41, 0.29)
1.24 (0.09, 2.39)
− 0.31 (− 1.27, 0.64)
− 0.15 (− 1.40, 1.09)
0.90 (− 0.33, 2.14)

0.68
0.72
0.72
0.24
0.16
0.24
0.20
0.01
0.53
0.33
0.06

a
The generalized mixed model include random intercept and random slope for year since enrollment, the crude model used repeated measures of eGFR from the 1st
to the 8th annual visit during DPPOS follow-up as the dependent variable and used baseline PFAS concentration (average between baseline and year 2 measures during
DPP, log-2 transformed), treatment arm, and year since randomization as the independent variables, the model also included a second and a third order spline term for
year (year*year and year*year*year); the adjusted model adjusted for baseline covariates including age, sex, race/ethnicity, education, marital status, income,
smoking status, menopause status, DASH diet score, hypertension status, and use of kidney medication. N = 875. The beta coefficient is interpreted as the mean
difference in eGFR (mL/min/1.73 m2) during DPPOS follow-up per doubling of baseline PFAS concentration.
b
Hypertension was defined as self-reported hypertension diagnosis, use of anti-hypertensive medications, or systolic/diastolic BP ≥ 140/90 mmHg.
c
pint: p-value of the interactive term between PFAS and baseline hypertension status (p < 0.1 suggests effect modification).
d
β (95% CI) = − 3.75 (− 5.83, − 1.68) for detected vs non-detected Sm2-PFOS.

concentration and longitudinal decline in kidney function (see eFig
ure 2 for DAG), significant longitudinal associations remained for Sm2PFOS and Sb-PFOS (eTable 3). Controlling for elevated ACR at baseline
strengthened the magnitude of inverse association between some plasma
PFAS and eGFR (eTable 3) which suggested potential negative con
founding by microalbuminuria (see eFigure 2 for DAG). We did not find
evidence of effect modification by sex or the initial lifestyle intervention
(eTable 4), but participants with baseline hypertension had greater
decreases in eGFR per doubling of plasma PFAS concentrations
(Table 3). The test for potential difference in the slope of eGFR decline
by adding an interaction term between time and PFAS yield statistically
insignificant result (Appendix A). Evaluation for reverse causation
showed that repeated measures of plasma PFAS concentrations did not
differ significantly by baseline eGFR level (data not shown). Analysis
using all eGFR data from Year 1 to Year 11 shows comparable findings
with associations of the same direction and similar magnitude, however,
most of the 95% confidence interval were wider and crossed the null
(data not shown). Sensitivity analyses using different imputed ages in
estimating the eGFR for the oldest age group (65+ years) showed
comparable estimates (beta changed less than 0.1), and all the statisti
cally significant findings remained excepted for the borderline signifi
cant n-PFOA (eTable 5).

who had available data (eFigure 1); participants’ characteristics were
comparable with study population of the main longitudinal analysis
(eTable 7). Most PFAS were not cross-sectionally associated with eGFR
at baseline, except for Sm2-PFOS [-4.66 (-8.29, − 1.04) mL/min/1.73 m2
per doubling or − 2.90 (-4.94, − 0.85) mL/min/1.73 m2 comparing
detectable vs non-detectable, eTable 8]. Consistent with longitudinal
findings, we detected effect modification by hypertension status (eTa
ble 8). There was no evidence of effect modification by sex or nonlin
earity of effect. As a mixture, baseline plasma concentrations of these 6
PFAS were not associated with baseline eGFR in this population [ψ:
− 3.26 (95% CI: − 1.63, 0.64) mL/min/1.73 m2 eGFR per quantile in
crease]. Baseline ACR was inversely associated with baseline PFOA and
EtFOSAA, and there was no evidence of effect modification by hyper
tension status (eTable 9) or baseline eGFR (data not shown).

3.3. PFAS as a mixture
Quantile g-computation estimated a one quartile increase in PFAS
mixtures to be associated with 2.26 (95% CI: − 4.12, − 0.39) mL/min/
1.73 m2 lower eGFR at year 5 in DPPOS, conditional on covariates. Sm2PFOS and Sb-PFOA contributed to most of the weight of the mixtures
(eTable 6). Estimated eGFR decreased linearly by quartile of PFAS
mixture concentrations (Fig. 1), and test of nonlinearity did not show
significant deviation from linear effect. Controlling for baseline eGFR
reduced the magnitude of the estimate but the effect remained statisti
cally significant [Ψ: − 1.81 (95% CI: − 3.57. − 0.04,) mL/min/1.73 m2
eGFR at DPPOS Year 5 per quartile increase) (eTable 6).
3.4. Cross-sectional association at baseline
We evaluated cross-sectional associations of plasma PFAS concen
trations with eGFR and ACR at baseline using data from 925 participants

Fig. 1. Mixture effect of 6 plasma PFAS concentrations on eGFR at DPPOS
Year 5.
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estimated a − 0.91 (-1.83, 0.00) mL/min/1.73 m2 lower eGFR per
natural-log (~2.7-fold) increase in serum PFOS (Wang et al., 2019); and
the US C8 Health Project (Mid-Ohio Valley, N = 29,641) estimated
− 0.98 (SE: 0.274, p = 0.0003) mL/min/1.73 m2 lower eGFR comparing
the 5th (>88 ng/mL) to the 1st quintile (<11.1 ng/mL) of serum PFOA,
cross-sectionally (Dhingra et al., 2017). The only available longitudinal
estimates were a study from 210 community residents living close to a
uranium processing site in Fernald, Ohio who also had high risk of
exposure of PFAS due to residential location (Blake et al., 2018). The
study had repeated measures of serum PFAS and eGFR over approxi
mately 10 years of follow-up (1999–2008). The latent models they
applied were comparable to the longitudinal model we used in this
analysis as both evaluated the longitudinal trend of eGFR in relation to a
baseline eGFR measurement. They found − 1.72 (− 3.29, − 0.15) mL/
min/1.73 m2 lower eGFR per quartile increase (approximately 30%
absolute increase) in serum PFOS adjusting for age, year of measure
ment, sex, education, income, BMI and marital status, which was com
parable to our finding [− 1.50 (− 2.81, − 0.19) mL/min/1.73 m2 lower
eGFR per doubling of PFOS]. Compared to Blake et al., our study had a
larger sample size and a narrower age range, therefore our estimates had
higher precision, which was evident by the narrower 95% confidence
interval. However, since our participants had fewer measures of blood
PFAS and eGFR, we did not apply the repeated measures approach as
done by Blake et al., thus, we cannot confirm their findings on the in
verse associations of PFHxS, PFNA, PFDA and the positive association of
MeFOSAA with eGFR. We should note that while this repeated measure
approach applied by Black et al. can gain more power, findings from this
method was also more likely to be biased by time-varying confounding
so care should be taken in interpreting the results. Similar to one pre
vious report (Wang et al., 2019), we observed stronger effects of the
branched PFOS and PFOA which have higher renal clearance rates
compared to linear isomers (Gao et al., 2015; Olsen et al., 2007; Russell
et al., 2015; Shi et al., 2016; Worley et al., 2017; Zhang et al., 2013). The
uptake of PFAS by organic anion transporters into the proximal renal
tubules regulates the active secretion and reabsorption of PFAS (Weaver
et al., 2010; Worley et al., 2017; Yang et al., 2010; Zhang et al., 2013).
The reabsorption of PFAS is hypothesized to alter normal kidney
function.
Impaired kidney function can also disrupt the balance of renal
secretion and reabsorption of PFAS which in term alters blood PFAS
concentrations (Olsen et al., 2007; Stanifer et al., 2018). Previous crosssectional study from US NHANES had shown an inverted U-shaped
relationship between PFAS and eGFR (Jain and Ducatman, 2019a),
suggesting that the level of absorption and secretion activities may be
differentially affected during progressive renal decline. Thus, caution
should be taken when using blood PFAS concentrations as a proxy of
PFAS exposure as it may underestimate the effect of PFAS on kidney
function, especially at the stage of advanced renal failure. In our study,
most participants had normal kidney function, so we may have been
unable to detect this inverted U-shape association. However, when we
additionally adjusted for baseline microalbuminuria or elevated ACR,
which often precede eGFR decline, the inverse association between
blood PFAS and eGFR strengthened, confirming the potential negative
confounding effect. The inverse relationship between blood PFAS con
centration and ACR was previously reported in NHANES (Jain and
Ducatman, 2019b). The study hypothesized that elevated ACR could
directly cause PFAS excretion, or that elevated ACR could also be a result
of a process that also reverses the reabsorption of PFAS by the kidney,
leading to higher PFAS excretion from urine and lower blood PFAS
concentrations. The role of protein-binding had been noted to alter PFAS
excretion (Beesoon and Martin, 2015); and a recent study also showed
that albumin is the major protein carrier for many long-chain PFAS
including PFOS, PFOA, PFHxS, PFDA and PFNA (Forsthuber et al.,
2020). Together this evidence shows that adjustment for albumin level
and stages of glomerular filtration function may have important impli
cations and further investigations are warranted.

4. Discussion
In this prospective analysis incorporating approximately 14 years of
kidney function data from prediabetic adults enrolled in the lifestyle and
placebo arms of the DPP trial, we observed that plasma concentrations of
select PFAS, individually and as a mixture, were associated with lower
mean eGFR over time, or declining kidney function. These results sup
port our initial hypothesis. However, we did not find evidence that
higher baseline PFAS was associated with greater slope of eGFR decline,
which could be due to the fact that most participants had normal kidney
function throughout the follow-up and our data was underpowered to
detect the difference in slope. Additionally there presumably was
decreasing PFAS exposure after baseline (1996–1999) due to manufac
tures’ phasing out of PFOS and PFOA (US EPA, 2016) which may have
attenuated the effect. While there is evidence on the adverse effect of
PFAS on kidney function (Ferrari et al., 2019; Stanifer et al., 2018; Zhao
et al., 2020), most prior epidemiological studies were cross-sectional,
thus limiting inferences on causality (Stanifer et al., 2018; Wang et al.,
2019), and the two available studies using longitudinal data showed
inconsistent results. Specifically, Black et al. observed repeated mea
sures of higher serum PFNA, PFHxS and PFDA and lower MeFOSAA were
significantly associated with lower longitudinal measures of eGFR, but
found null association between PFOA and eGFR (Blake et al., 2018).
Dhingra et al., on the other hand, observed significant association be
tween PFOA and eGFR, but only when using PFOA concentration
measured in the serum (cross-sectional analysis only). When they eval
uated the longitudinal data with modelled PFOA serum concentrations
based on external exposure, such association did not exist which led
them to conclude the observed association between higher serum PFOA
and reduced eGFR was a result of reverse causation (Dhingra et al.,
2017). While we cannot perform a randomized intervention to examine
the causal effect of PFAS exposure on kidney function, our study utilized
a prospective study design and implemented multiple tests of reverse
causation to establish the temporality of the relationship in order to
provide a more definitive evidence of the causal influence of PFAS on
kidney function. We estimated that each doubling of baseline PFOS
concentrations were associated with 1.50 mL/min/1.73 m2 (95% CI:
− 2.81, − 0.19) lower eGFR during the study follow-up; and as a mixture,
each quartile increase in baseline PFAS was associated with 2.26 mL/
min/1.73 m2 (95% CI: − 4.12, − 0.39) lower eGFR at the 5th annual
follow-up visits of DPPOS controlling for age, sex, race/ethnicity, edu
cation, marital status, income, smoking status, baseline menopause
status, baseline diet score, treatment arm, and baseline blood pressure.
When additionally controlled for baseline eGFR, the effect estimates
attenuated somewhat but still stayed statistically significant. While this
effect may not translate to immediate clinical manifestation on kidney
health, over time and at the population level, PFAS exposure may
negatively affect the kidney and compound the effects of other risk
factors. Contrary to our hypothesis, we did not find evidence that the
PFAS-associated decreases in eGFR were modified by an initial lifestyle
intervention targeting diet, exercise and behavioral changes. However,
all participants were offered a modified lifestyle intervention after the
unblinding of the DPP intervention (Diabetes Prevention Program
Research Group, 2015; Diabetes Prevention Program Research Group
et al., 2009; Goldberg et al., 2017), thus, the differential effect across the
lifestyle and placebo arm might be diluted, and additional investigation
is needed.
Our study observed comparable findings with some previous studies
(Shankar et al., 2011; Zhao et al., 2020). Cross-sectional analyses using
U.S. NHANES data (1999–2008, N = 4857 adults) showed those with the
highest quartile of serum PFOS and PFOA concentration (PFOS > 29.5
ng/mL, PFOA: >5.9 ng/mL) had 6.7 and 5.7 mL/min/1.73 m2 lower
eGFR compared to those with the 1st quartile concentrations (PFOS:
<11.7 ng/mL, PFOA: <2.8 ng/mL); and the odds of CKD were 82% and
73% higher, respectively (Shankar et al., 2011). Consistently, the China
C8 Study [N = 1612, median (IQR) PFOS 24.2 (14.6, 37.2) ng/mL]
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Control and Prevention (CDC). Use of trade names is for identification
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Unreported in previous literature, we observed differential effect by
hypertension status. Hypertension may accelerate renal damage and
increase the susceptibility of CKD for patients with diabetes (Mennuni
et al., 2014). Our previous analysis showed plasma PFAS concentrations
were not associated with blood pressure (Lin et al., 2020a), thus hy
pertension was unlikely an intermediate variable in the causal pathway.
In the hypertensive state, the kidney experiences alteration of vascular
structure, change in glomerular permeability to macromolecules, and
increase in glomerular, tubular and interstitial injuries (Folkow et al.,
1977; Mennuni et al., 2014) which could intensify the damage of PFAS
on kidney function. Hypertensive patients often experienced micro
albuminuria (Palatini, 2003; Rodicio et al., 1998), and the severity of
microalbuminuria correlates with the severity of hypertension and re
sponses to lowering of blood pressure levels (Parving et al., 1974). Other
mechanisms that may promote renal damage include oxidative stress,
endothelial dysfunction, and genetic and epigenetic factors. Additional
studies are needed to better understand this differential effect.
Important strengths of our current study included the long follow-up
time, prospective assessments of exposure and eGFR, multiple sensitivity
analyses and tests of reverse causation to ensure the internal validity and
robustness of detected associations. The current longitudinal findings fill
a significant gap in the current literature (Stanifer et al., 2018). The gcomputation approach provided a framework to estimate the overall
effect of the multiple PFAS chemicals.
Limitations include: limited generalizability because of participants’
characteristics (all had overweight/obesity and prediabetes); potential
unmeasured confounders, such as blood iron level, genetics and epige
netic variants; and findings from the 6 PFAS we examined in this study
may not be generalizable to other, newer PFAS. Renal clearance of PFAS
vary by carbon-chain length, side-chain functional groups and isomeric
structure, and continued monitoring of the potential adverse effects of
PFAS on kidney health is needed.

Appendix A. Supplementary material
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.envint.2020.106375.
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